Company intelligence / Profile preview

Carina Biotech

Adelaide, South Australia, Australiacarinabiotech.com ↗

Ownership: Private
Employees: ~16
Development stage: Phase 1

Overview

Lead candidate CNA3103 targeting LGR5 is in Phase 1/2a clinical trials for metastatic colorectal cancer with early promising clinical results. The trial is designed to enroll up to 44 patients with metastatic disease who have failed prior lines of chemotherapy and express LGR5 on their cancer cells.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyAdoptive cell therapies
Industry: Biotech

Drug pipeline

5 assets

CNA3103

4 more assets in the full pipeline.

Request access →

Partnerships

Biosceptre (sold IP rights to first lead CAR-T cell)

Beyond the preview

Go deeper on Carina Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carina Biotech.

Explore the full profile